Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes

6-Months Exenatide and Glucose Homeostasis Determinants in Type 2 Diabetic Patients

The purpose of this study is to determine in type 2 diabetic patients in secondary failure to combined oral therapy whether, besides improvement in glycemic control, addition of exenatide, a new drug introduced to treat diabetes before addition of insulin to current therapy, over 6 months is associated with improvement in beta-cell function, insulin sensitivity following 24-hours discontinuation of the drug.

Inclusion Criteria:

• type 2 diabetes subjects
• 40 to 80 years
• body mass index (BMI) between 25 and 40 kg/m²
• baseline glycated haemoglobin (HbA1c) > 7.0 %, despite a maximally-tolerated combined oral therapy with a BCF stimulant (sulfonylurea or repaglinide) plus metformin

Exclusion Criteria:

• previous or current use of glitazone
• previous use of systemic glucocorticoids, weight-reducing drug(s) such as sibutramine
• previous exposure to GLP-1 receptor agonist or DPP-4 inhibitors